Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Total Liabilities (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Total Liabilities over the past 15 years, most recently at $191.9 million for Q2 2025.

  • Quarterly results put Total Liabilities at $191.9 million for Q2 2025, down 4.07% from a year ago — trailing twelve months through May 2025 was $191.9 million (down 4.07% YoY), and the annual figure for FY2025 was $191.9 million, down 4.07%.
  • Total Liabilities for Q2 2025 was $191.9 million at Lifecore Biomedical, Inc. \De\, up from $190.3 million in the prior quarter.
  • Over the last five years, Total Liabilities for LFCR hit a ceiling of $304.7 million in Q1 2021 and a floor of $163.1 million in Q1 2023.
  • Median Total Liabilities over the past 5 years was $201.8 million (2023), compared with a mean of $214.4 million.
  • Biggest five-year swings in Total Liabilities: tumbled 40.36% in 2022 and later rose 16.9% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Total Liabilities stood at $265.9 million in 2021, then fell by 22.96% to $204.8 million in 2022, then dropped by 0.66% to $203.5 million in 2023, then fell by 3.86% to $195.6 million in 2024, then decreased by 1.9% to $191.9 million in 2025.
  • The last three reported values for Total Liabilities were $191.9 million (Q2 2025), $190.3 million (Q1 2025), and $195.6 million (Q4 2024) per Business Quant data.